ReShape Lifesciences (OTCMKTS:RSLSD) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.
Insider & Institutional Ownership
89.1% of LivaNova shares are owned by institutional investors. 0.5% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
ReShape Lifesciences has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
This is a breakdown of recent recommendations for ReShape Lifesciences and LivaNova, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
LivaNova has a consensus price target of $63.57, indicating a potential downside of 22.86%.
This table compares ReShape Lifesciences and LivaNova’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares ReShape Lifesciences and LivaNova’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ReShape Lifesciences||$610,000.00||0.00||-$81.15 million||N/A||N/A|
|LivaNova||$1.08 billion||3.70||-$155.18 million||$3.08||26.76|
ReShape Lifesciences has higher earnings, but lower revenue than LivaNova.
LivaNova beats ReShape Lifesciences on 7 of the 9 factors compared between the two stocks.
About ReShape Lifesciences
ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CVÂ) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC has a research collaboration with Verily to gain insights into Vagus nerve stimulation impact on difficult-to-treat depression. The company was founded in 1987 and is headquartered in London, the United Kingdom.
Receive News & Ratings for ReShape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReShape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.